Free Trial
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Eliem Therapeutics logo
$1.42 +0.05 (+3.65%)
As of 07/14/2025

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Key Stats

Today's Range
$1.35
$1.45
50-Day Range
$1.17
$1.42
52-Week Range
$2.35
$11.55
Volume
165,418 shs
Average Volume
486,688 shs
Market Capitalization
$42.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
See More Headlines

ELYM Stock Analysis - Frequently Asked Questions

Eliem Therapeutics' stock was trading at $1.80 on January 1st, 2025. Since then, ELYM stock has decreased by 21.1% and is now trading at $1.42.

Eliem Therapeutics, Inc. (NASDAQ:ELYM) posted its earnings results on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.19.

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/08/2021
Today
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELYM
CIK
1768446
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.12 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-47.03%
Return on Assets
-45.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
60.41
Quick Ratio
60.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.36

Miscellaneous

Outstanding Shares
29,752,000
Free Float
28,354,000
Market Cap
$42.25 million
Optionable
Not Optionable
Beta
-0.39
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ELYM) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners